Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Probable levetiracetam-related serum alkaline phosphatase elevation.

Xiong N, Hou L, Lu N, Mohamed AA, Wang T, Huang Y.

BMC Neurol. 2012 Sep 20;12:97. doi: 10.1186/1471-2377-12-97.

3.

The bone mineral content alterations in pediatric patients medicated with levetiracetam, valproic acid, and carbamazepine.

Serin HM, Koç ZP, Temelli B, Esen İ.

Epilepsy Behav. 2015 Oct;51:221-4. doi: 10.1016/j.yebeh.2015.06.025.

PMID:
26298867
4.

Levetiracetam induced acute reversible psychosis in a patient with uncontrolled seizures.

Kumar N, Swaroop HS, Chakraborty A, Chandran S.

Indian J Pharmacol. 2014 Sep-Oct;46(5):560-1. doi: 10.4103/0253-7613.140599.

5.

The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study.

Rosenow F, Schade-Brittinger C, Burchardi N, Bauer S, Klein KM, Weber Y, Lerche H, Evers S, Kovac S, Hallmeyer-Elgner S, Winkler G, Springub J, Niedhammer M, Roth E, Eisensehr I, Berrouschot J, Arnold S, Schröder M, Beige A, Oertel WH, Strzelczyk A, Haag A, Reif PS, Hamer HM; LaLiMo Study Group..

J Neurol Neurosurg Psychiatry. 2012 Nov;83(11):1093-8. doi: 10.1136/jnnp-2011-301999.

PMID:
22595362
6.

Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison.

Bootsma HP, Ricker L, Diepman L, Gehring J, Hulsman J, Lambrechts D, Leenen L, Majoie M, Schellekens A, de Krom M, Aldenkamp AP.

Seizure. 2008 Jan;17(1):19-26.

7.

Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany.

Opp J, Tuxhorn I, May T, Kluger G, Wiemer-Kruel A, Kurlemann G, Gross-Selbeck G, Rating D, Brandl U, Bettendorf U, Härtel C, Korn-Merker E.

Seizure. 2005 Oct;14(7):476-84.

8.

[Follow-up study on levetiracetam monotherapy in children with epilepsy].

Gao ZJ, Jiang YW.

Zhongguo Dang Dai Er Ke Za Zhi. 2008 Dec;10(6):711-4. Chinese.

PMID:
19102836
9.

Levetiracetam monotherapy in juvenile myoclonic epilepsy.

Sharpe DV, Patel AD, Abou-Khalil B, Fenichel GM.

Seizure. 2008 Jan;17(1):64-8.

10.

Levetiracetam: Probably Associated Diurnal Frequent Urination.

Ju J, Zou LP, Shi XY, Hu LY, Pang LY.

Am J Ther. 2016 Mar-Apr;23(2):e624-7. doi: 10.1097/MJT.0000000000000201.

PMID:
26938751
11.

Effect of age and comedication on levetiracetam pharmacokinetics and tolerability.

Hirsch LJ, Arif H, Buchsbaum R, Weintraub D, Lee J, Chang JT, Resor SR Jr, Bazil CW.

Epilepsia. 2007 Jul;48(7):1351-9.

12.

[Clinical efficacy of the novel antiepileptic agent levetiracetam: evaluation in patients with localization-related epilepsy].

Yamazoe T, Fujimoto A, Yamazaki M, Yokota T, Okanishi T, Uchiyama T, Ohashi T, Tanaka T, Enoki H, Yamamoto T.

Brain Nerve. 2012 Oct;64(10):1169-74. Japanese.

PMID:
23037607
13.

[Effectiveness and safety of long-term levetiracetam treatment in patients with refractory epilepsy].

Matsuo M, Fuji A, Matsuzaka T, Baba H, Toda K, Ono T, Tanaka S, Sato T, Moriuchi H.

No To Hattatsu. 2015 Jul;47(4):272-8. Japanese.

PMID:
26353448
14.

Probable levetiracetam-associated depression in the elderly: two case reports.

Vande Griend JP, Linnebur SA, Bainbridge JL.

Am J Geriatr Pharmacother. 2009 Oct;7(5):281-4. doi: 10.1016/j.amjopharm.2009.10.002.

PMID:
19948304
15.

[Effectiveness and tolerability of levetiracetam in 43 children and adolescents with epilepsy].

Herranz JL, Rufo-Campos M, Arteaga R.

Rev Neurol. 2003 Dec 1-15;37(11):1005-8. Spanish.

16.

A prospective analysis of the outcome of levetiracetam in clinical practice.

Nicolson A, Lewis SA, Smith DF.

Neurology. 2004 Aug 10;63(3):568-70.

PMID:
15304598
17.

The adverse event profile of levetiracetam: A meta-analysis on children and adults.

Verrotti A, Prezioso G, Di Sabatino F, Franco V, Chiarelli F, Zaccara G.

Seizure. 2015 Sep;31:49-55. doi: 10.1016/j.seizure.2015.07.004.

18.

KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy.

Trinka E, Marson AG, Van Paesschen W, Kälviäinen R, Marovac J, Duncan B, Buyle S, Hallström Y, Hon P, Muscas GC, Newton M, Meencke HJ, Smith PE, Pohlmann-Eden B; KOMET Study Group..

J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1138-47. doi: 10.1136/jnnp-2011-300376.

PMID:
22933814
19.

Hair loss with levetiracetam in five patients with epilepsy.

Zou X, Hong Z, Zhou D.

Seizure. 2014 Feb;23(2):158-60. doi: 10.1016/j.seizure.2013.11.007.

20.

Retention rate of levetiracetam in children with intractable epilepsy at 1 year.

Peake D, Mordekar S, Gosalakkal J, Mukhtyar B, Buch S, Crane J, Wheway R, Rittey C, Donnelly J, Whitehouse WP, Philip S.

Seizure. 2007 Mar;16(2):185-9.

Supplemental Content

Support Center